Lipitor Lawsuits Mount, as Bernstein Liebhard LLP Notes Publication of New Study Investigating Impact of Revised Statin Guidelines

The Firm is evaluating Lipitor lawsuits on behalf of patients who allegedly developed Type-2 diabetes due to their use of the statin medication.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
Hundreds of lawsuits that allege a link between the use of Lipitor and diabetes are already making their way through U.S. court.

New York, New York (PRWEB) April 11, 2014

As hundreds of Lipitor lawsuits ( )
continue to move forward in federal court, Bernstein Liebhard LLP notes the publication of a new study that examines the potential impact of new statin guidelines issued last year by the American College of Cardiology and American Heart Association. According to the study, which was published April 9th in the Journal of the American Medical Association, if the new guidelines are implemented in Europe, drugs like Lipitor would be recommended in 96.4% of men and 65.8% of men with a mean age of 65.5. *

In reaching those conclusions, the authors of the study applied the new statin guidelines to 4,854 patients over the age of 55 who participated in an earlier European study that was conducted from 1997 to 2001. When the research team used the new guidelines to calculate the risk of cardiovascular disease among the participants, it was suggested that more than 21% of patients would develop hard atherosclerotic cardiovascular disease. In reality, just over 12% developed the condition.

“Hundreds of lawsuits that allege a link between the use of Lipitor and diabetes are already making their way through U.S. courts. These findings, taken together with the risks potentially associated with stains, would suggest the new guidelines need further evaluation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.

Lipitor Diabetes Allegations
The U.S. Food & Drug Administration (FDA) announced in February 2012 that it had asked the manufacturers of Lipitor and other statins to add new information to their product labels regarding a possible increased risk of Type 2 diabetes. The action was prompted by a study published in JAMA: Internal Medicine in January 2012 that reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes. * *

In May 2013, the British Medical Journal also reported an association between Lipitor and diabetes, finding that patients who took the drug had a 22 percent increased risk of new-onset diabetes.***

According to court documents, at least 270 Lipitor lawsuits have been filed in a consolidated litigation underway in the U.S. District Court, District of South Carolina, on behalf of patients who allegedly developed new-onset Type 2 diabetes due to their use of Lipitor. Among other things, the complaints allege that Pfizer Inc. was aware of this risk, but concealed this information in order to protect sales of the statin. Plaintiffs further allege that they would never have used Lipitor had Pfizer provided adequate warnings regarding the association with Lipitor and diabetes, and assert that the warnings added to label in 2012 remain inadequate. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

Individuals who developed new-onset Type 2 diabetes allegedly related to their use of Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. Find out more about filing a Lipitor lawsuit at Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.

*, JAMA, April 9, 2014
**, JAMA Internal Medicine, January 2012
***, BMJ, May 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com